NASDAQ:UBX - Unity Biotechnology Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.66 -0.04 (-0.46 %)
(As of 05/22/2019 07:13 AM ET)
Previous Close$8.70
Today's Range$8.5504 - $8.91
52-Week Range$7.39 - $24.56
Volume95,386 shs
Average Volume186,563 shs
Market Capitalization$371.57 million
P/E RatioN/A
Dividend YieldN/A
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.

Receive UBX News and Ratings via Email

Sign-up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:UBX



Sales & Book Value

Annual SalesN/A



Market Cap$371.57 million
Next Earnings Date8/8/2019 (Estimated)
OptionableNot Optionable

Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology Inc (NASDAQ:UBX) released its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.44) EPS for the quarter, topping the Zacks' consensus estimate of ($0.47) by $0.03. View Unity Biotechnology's Earnings History.

When is Unity Biotechnology's next earnings date?

Unity Biotechnology is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Unity Biotechnology.

What price target have analysts set for UBX?

5 brokers have issued 12-month price objectives for Unity Biotechnology's shares. Their forecasts range from $17.00 to $33.00. On average, they expect Unity Biotechnology's share price to reach $25.40 in the next twelve months. This suggests a possible upside of 193.3% from the stock's current price. View Analyst Price Targets for Unity Biotechnology.

What is the consensus analysts' recommendation for Unity Biotechnology?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Unity Biotechnology.

What are Wall Street analysts saying about Unity Biotechnology stock?

Here are some recent quotes from research analysts about Unity Biotechnology stock:
  • 1. According to Zacks Investment Research, "UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company's product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States. " (5/14/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We are initiating coverage on UNITY Overweight rating and 12-month PT of $21. UNITY is making progress on treatments that could extend healthspan, a longer disease-free state, by targeting indications that are associated with aging. UNITY focuses on eliminating senescent cells, the precursors to disease progression. Lead product UBX0101 is in Phase 1 development for osteoarthritis (OA), with proof-of-concept data expected in 2Q19." (3/6/2019)

Has Unity Biotechnology been receiving favorable news coverage?

News coverage about UBX stock has trended somewhat positive this week, InfoTrie reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Unity Biotechnology earned a daily sentiment score of 1.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.

Who are some of Unity Biotechnology's key competitors?

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include Canopy Growth (CGC), IQIYI (IQ), AbbVie (ABBV), Biohaven Pharmaceutical (BHVN), AVEO Pharmaceuticals (AVEO), BioTelemetry (BEAT), Clovis Oncology (CLVS), Fate Therapeutics (FATE), Amicus Therapeutics (FOLD) and GW Pharmaceuticals PLC- (GWPH).

Who are Unity Biotechnology's key executives?

Unity Biotechnology's management team includes the folowing people:
  • Mr. Keith R. Leonard Jr., Exec. Chairman & CEO (Age 57)
  • Dr. Nathaniel E. David, Co-Founder, Pres & Exec. Director (Age 51)
  • Mr. Robert C. Goeltz II, Chief Financial Officer (Age 46)
  • Dr. Jan M. van Deursen, Founder
  • Dr. Judith Campisi, Founder

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an IPO on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

Who are Unity Biotechnology's major shareholders?

Unity Biotechnology's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (10.61%), BlackRock Inc. (4.42%), Morgan Stanley (1.05%), Goldman Sachs Group Inc. (0.79%), Northern Trust Corp (0.55%) and Jacobs Levy Equity Management Inc. (0.08%).

Which institutional investors are selling Unity Biotechnology stock?

UBX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Wells Fargo & Company MN and Gilder Gagnon Howe & Co. LLC.

Which institutional investors are buying Unity Biotechnology stock?

UBX stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, BlackRock Inc., Jacobs Levy Equity Management Inc., State of Wisconsin Investment Board, New York State Common Retirement Fund, SG Americas Securities LLC and Cerity Partners LLC.

How do I buy shares of Unity Biotechnology?

Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $8.66.

How big of a company is Unity Biotechnology?

Unity Biotechnology has a market capitalization of $371.57 million. Unity Biotechnology employs 106 workers across the globe.

MarketBeat Community Rating for Unity Biotechnology (NASDAQ UBX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  58 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  122
MarketBeat's community ratings are surveys of what our community members think about Unity Biotechnology and other stocks. Vote "Outperform" if you believe UBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/22/2019 by Staff

Featured Article: Ex-Dividend

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel